Customized Semaglutide Weight Loss Program at Seattle Plastic Surgery
SEATTLE, WA / ACCESSWIRE / July 28, 2023 / Semaglutide is the latest approved medication for weight loss. Mimicking a hormone that contributes to feelings of fullness and hunger, semaglutide also helps speed up the metabolism over time. Combined with lifestyle changes like diet and exercise, it can help patients lose up to 15% or more of their body weight.
The providers at Seattle Plastic Surgery created a semaglutide Weight Loss Program that is customizable for each patient. The program includes custom doses of semaglutide in injection or pill form, a diet and exercise plan, and monthly follow-up appointments. It is charged monthly and after the initial consultation, the medication and all necessary supplies are available to the patient. Appointments can take place in person or virtually.
Seattle Plastic Surgery’s Semaglutide Weight Loss Program is unique because it is fully customizable for the patient. The diet and exercise plans are easily adjusted to accommodate existing dietary restrictions and the patient’s abilities. The dosage of the semaglutide is adjusted monthly by the provider to tailor the weight loss for the patient. The comprehensive semaglutide treatment in Seattle aims to help patients find and sustain significant weight loss.
The cost of the Seattle Semaglutide Weight Loss Program is as follows:
To better serve patients throughout the Seattle area, Seattle Plastic Surgery offers three locations:
Seattle Plastic Surgery
contactus@seattleplasticsurgery.com
206-324-1120
SOURCE: Seattle Plastic Surgery
View source version on accesswire.com:
https://www.accesswire.com/770788/Seattle-Plastic-Surgery-Now-Offering-Semaglutide-for-Weight-Loss-in-Seattle-Bellevue-Kirkland
MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…
TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…
mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…
Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…